All you need to know about BTKi in chronic Lymphocytic leukemia

Since 2014, the advent of targeted therapies, particularly BTK inhibitors in the context of chronic leukemic leukemia, has significantly improved the prognosis of patients and implied a change in our practices. The second generation BTK inhibitors were developed after ibrutinib, allowing a better tolerance, and more recently the non-covalent BTK inhibitors offer a new therapeutic option in case of resistance to covalent BTK inhibitors. This article reviews the characteristics of BTK inhibitors, the main therapeutic results along with both toxicity and resistance mechanisms., toxicity and resistance mechanisms.